Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Total Cold Medicine A - Kunihiro is an over-the-counter (OTC) multi-symptom cold remedy developed and marketed by Kokando Pharmaceutical Co., Ltd. in Japan. As a small molecule combination product, its primary active ingredient is ibuprofen, which serves as an antipyretic and analgesic to alleviate fever, headache, and joint pain. The formulation also includes additional active agents such as antihistamines (e.g., d-chlorpheniramine maleate) to treat runny nose and sneezing, decongestants/bronchodilators (e.g., dl-methylephedrine hydrochloride) for nasal stuffiness, and antitussives (e.g., dihydrocodeine phosphate) to suppress coughing. It is indicated for the relief of various symptoms associated with the common cold and is regulated as a Class 2 OTC drug in the Japanese market, specifically designed for use by adults aged 15 and older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Total Cold Medicine A - Kunihiro.